About

BioSig Tech (NASDAQ: BSGM) is a medical device company that aims to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. This company is led by a proven management team and a world-class Board of Directors.

BioSig Tech focuses on delivering the technology in order to improve Atrial Fibrillation and Ventricular Tachycardia. For this reason, it has developed the PURE EP™ System, an advanced biomedical signal processing technology. This innovative platform offers potential benefits over current technologies. It provides increased accuracy, reduced noise, and interference, clinical information previously not available and potential elimination of the need for repeat procedures.

The PURE EP™ System was designed to assist electrophysiologists in making crucial clinical decisions in real-time. The PURE EP™ System is designed by the medical device company, BioSig Tech, to assist electrophysiologists in making crucial clinical decisions in real-time.

This surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system, acquires and displays high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy. The PURE EP™ System provides assistance in identifying appropriate catheter ablation targets.

Also, the system offers benefits over current technologies such as increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures.

The medical device company BioSig Tech has partnered with Minnetronix on technology development. Additionally, it has received FDA 510(k) clearance for the PURE EP™ System in 2018.